J-J Shieh1, C-J Pan, B C Mansfield, J Y Chou. 1. Section on Cellular Differentiation, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1830, USA.
Abstract
AIMS/HYPOTHESIS: There are three members of the glucose-6-phosphatase (G6Pase) family: (1) the liver/kidney/intestine G6Pase-alpha (encoded by G6PC), which is a key enzyme in glucose homeostasis; (2) the ubiquitous G6Pase-beta (encoded by G6PC3); and (3) the islet-specific G6Pase-related protein (IGRP, encoded by /G6PC2). While G6Pase-alpha and G6Pase-beta are functional glucose-6-phosphate hydrolases, IGRP possesses almost no hydrolase activity. This was unexpected since G6Pase-alpha is more closely related to IGRP than G6Pase-beta. Recently, amino acids 206-214 in IGRP were identified as a beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes, suggesting that this peptide confers functional specificity to IGRP. We therefore investigated the molecular events that inactivate IGRP activity and the effects of the beta cell antigen sequence on the stability and enzymatic activity of G6Pase-alpha. METHODS: Studies were performed using site-directed mutagenesis and transient expression assays. Protein stability was evaluated by Western blotting, proteasome inhibitor studies and in vitro transcription-translation. RESULTS: We showed that the residues responsible for G6Pase activity are more extensive than previously recognised. Introducing the IGRP antigenic motif into G6Pase-alpha does not completely destroy activity, although it does destabilise the protein. The low hydrolytic activity in IGRP is due to the combination of multiple independent mutations. CONCLUSIONS/ INTERPRETATION: The loss of catalytic activity in IGRP arises from the sum of many sequence differences. G6Pase-alpha mutants containing the beta cell antigen sequence are preferentially degraded in cells, which prevents targeting by pathogenic CD8+ T cells. It is possible that IGRP levels in beta cells could dictate susceptibilities to diabetes.
AIMS/HYPOTHESIS: There are three members of the glucose-6-phosphatase (G6Pase) family: (1) the liver/kidney/intestine G6Pase-alpha (encoded by G6PC), which is a key enzyme in glucose homeostasis; (2) the ubiquitous G6Pase-beta (encoded by G6PC3); and (3) the islet-specific G6Pase-related protein (IGRP, encoded by /G6PC2). While G6Pase-alpha and G6Pase-beta are functional glucose-6-phosphate hydrolases, IGRP possesses almost no hydrolase activity. This was unexpected since G6Pase-alpha is more closely related to IGRP than G6Pase-beta. Recently, amino acids 206-214 in IGRP were identified as a beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes, suggesting that this peptide confers functional specificity to IGRP. We therefore investigated the molecular events that inactivate IGRP activity and the effects of the beta cell antigen sequence on the stability and enzymatic activity of G6Pase-alpha. METHODS: Studies were performed using site-directed mutagenesis and transient expression assays. Protein stability was evaluated by Western blotting, proteasome inhibitor studies and in vitro transcription-translation. RESULTS: We showed that the residues responsible for G6Pase activity are more extensive than previously recognised. Introducing the IGRP antigenic motif into G6Pase-alpha does not completely destroy activity, although it does destabilise the protein. The low hydrolytic activity in IGRP is due to the combination of multiple independent mutations. CONCLUSIONS/ INTERPRETATION: The loss of catalytic activity in IGRP arises from the sum of many sequence differences. G6Pase-alpha mutants containing the beta cell antigen sequence are preferentially degraded in cells, which prevents targeting by pathogenic CD8+ T cells. It is possible that IGRP levels in beta cells could dictate susceptibilities to diabetes.
Authors: C C Martin; L J Bischof; B Bergman; L A Hornbuckle; C Hilliker; C Frigeri; D Wahl; C A Svitek; R Wong; J K Goldman; J K Oeser; F Leprêtre; P Froguel; R M O'Brien; J C Hutton Journal: J Biol Chem Date: 2001-04-10 Impact factor: 5.157
Authors: A Bonnefond; N Bouatia-Naji; A Simon; C Saint-Martin; A Dechaume; P de Lonlay; M Polak; C Bellanné-Chantelot; P Froguel; M Vaxillaire Journal: Diabetologia Date: 2009-02-24 Impact factor: 10.122
Authors: C S Rose; N Grarup; N T Krarup; P Poulsen; L Wegner; T Nielsen; K Banasik; K Faerch; G Andersen; A Albrechtsen; K Borch-Johnsen; J O Clausen; T Jørgensen; A Vaag; O Pedersen; T Hansen Journal: Diabetologia Date: 2009-08-08 Impact factor: 10.122
Authors: Cyrus C Martin; Brian P Flemming; Yingda Wang; James K Oeser; Richard M O'Brien Journal: J Mol Endocrinol Date: 2008-08-27 Impact factor: 5.098
Authors: David Philipp Wohlfart; Bowen Lou; Chiara Simone Middel; Jakob Morgenstern; Thomas Fleming; Carsten Sticht; Ingrid Hausser; Rüdiger Hell; Hans-Peter Hammes; Julia Szendrödi; Peter Paul Nawroth; Jens Kroll Journal: Redox Biol Date: 2022-01-26 Impact factor: 11.799
Authors: Nabila Bouatia-Naji; Amélie Bonnefond; Devin A Baerenwald; Marion Marchand; Marco Bugliani; Piero Marchetti; François Pattou; Richard L Printz; Brian P Flemming; Obi C Umunakwe; Nicholas L Conley; Martine Vaxillaire; Olivier Lantieri; Beverley Balkau; Michel Marre; Claire Lévy-Marchal; Paul Elliott; Marjo-Riitta Jarvelin; David Meyre; Christian Dina; James K Oeser; Philippe Froguel; Richard M O'Brien Journal: Diabetes Date: 2010-07-09 Impact factor: 9.461
Authors: Wei-Min Chen; Michael R Erdos; Anne U Jackson; Richa Saxena; Serena Sanna; Kristi D Silver; Nicholas J Timpson; Torben Hansen; Marco Orrù; Maria Grazia Piras; Lori L Bonnycastle; Cristen J Willer; Valeriya Lyssenko; Haiqing Shen; Johanna Kuusisto; Shah Ebrahim; Natascia Sestu; William L Duren; Maria Cristina Spada; Heather M Stringham; Laura J Scott; Nazario Olla; Amy J Swift; Samer Najjar; Braxton D Mitchell; Debbie A Lawlor; George Davey Smith; Yoav Ben-Shlomo; Gitte Andersen; Knut Borch-Johnsen; Torben Jørgensen; Jouko Saramies; Timo T Valle; Thomas A Buchanan; Alan R Shuldiner; Edward Lakatta; Richard N Bergman; Manuela Uda; Jaakko Tuomilehto; Oluf Pedersen; Antonio Cao; Leif Groop; Karen L Mohlke; Markku Laakso; David Schlessinger; Francis S Collins; David Altshuler; Gonçalo R Abecasis; Michael Boehnke; Angelo Scuteri; Richard M Watanabe Journal: J Clin Invest Date: 2008-07 Impact factor: 14.808